Aligos Therapeutics
ALGS4.7400.21% ( -0.010 )
Aligos Therapeutics (ALGS)
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver...
- Open
- 4.740
- High
- 4.870
- Low
- 4.670
- Prev. Close
- 4.750
- Volume
- 71.83K
- Turnover
- 342.68K
- Avg Price
- 4.771
- Bid/Ask Ratio
- --
- Amplitude
- 4.21%
- 52wk High
- 13.689
- Volume Ratio
- 0.52
- Turnover Ratio
- 1.97%
Aligos Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 14, 2026Price forecast
$56.291087.46%
Forecast & RatingStrong buy
7analysts
- Strong buy85.71%
- Buy14.29%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 30 at 07:03 AM
Aligos Therapeutics to report Q2 2026 financial results
- PUBT · Jul 13 at 07:05 AM
Aligos completes enrollment in Phase 2 B-SUPREME trial for chronic hepatitis B drug pevifoscorvir sodium
- benzinga_article · Jul 6 at 04:05 PM
12 Health Care Stocks Moving In Monday's After-Market Session
- PUBT · Jul 6 at 03:05 PM
Aligos Therapeutics receives USD 25 million upfront in Greater China pevifoscorvir license deal with Amoytop
- PUBT · Jun 26 at 03:03 PM
Aligos Therapeutics shareholders approve ESPP share reserve increase, remove evergreen provision
- TradingView · Jun 24 at 03:36 PM
Lawrence M. Blatt Discloses Investment at Aligos Therapeutics with 5.6% Stake
